Residual Normal Renal Parenchymal and Tumor Volume in Tumor Surgeries
- Status
- UNKNOWN
- Phase
- N/A
Clinical Trials Related to Renal Cell Carcinoma
Related studies linked through entity extraction aliases.
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Meta-analysis of the Prognostic Value of Lymphocyte to Monocyte Ratio (LMR) in Non-metastatic Renal Cell Carcinoma.
- Status
- UNKNOWN
- Phase
- N/A
Laparoscopic Partial Nephrectomy for cT1 Tumors
- Status
- COMPLETED
- Phase
- N/A
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief
- Status
- UNKNOWN
- Phase
- NA
Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
- Status
- TERMINATED
- Phase
- PHASE1
Sintilimab in FH-deficient Renal Cell Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.
- Status
- UNKNOWN
- Phase
- PHASE2
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
- Status
- TERMINATED
- Phase
- N/A
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Prospective Trial for Examining Hematuria Using Computed Tomography
- Status
- COMPLETED
- Phase
- NA
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
- Status
- TERMINATED
- Phase
- PHASE1
Patient Reported Outcome After Nephron Sparing Treatment of Small Renal Tumours
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
The Registry of Oncology Outcomes Associated with Testing and Treatment
- Status
- COMPLETED
- Phase
- N/A
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2